A new company, Ascidian Therapeutics, is launching with a focus on treating human diseases by rewriting RNA. With an initial focus on replacing mutated exons at the RNA level, Ascidian’s technology enables targeting of large genes and genes with high mutational variance while maintaining native gene expression patterns and levels. This approach is designed to reduce risks associated with DNA editing and manipulation.
